<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879554</url>
  </required_header>
  <id_info>
    <org_study_id>B1121003</org_study_id>
    <nct_id>NCT00879554</nct_id>
  </id_info>
  <brief_title>A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors</brief_title>
  <acronym>CVX-045-101</acronym>
  <official_title>A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine safety and tolerability of CVX-045 in patients with
      advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine safety and tolerability of CVX-045 as weekly intravenous (IV) infusions in adult patients with advanced solid tumors</measure>
    <time_frame>Throughout duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify and characterize CVX-045-related adverse events (AEs)</measure>
    <time_frame>Throughout duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the plasma pharmacokinetics (PK) of CVX-045</measure>
    <time_frame>Days 1, 4, 8, 15, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine a recommended Phase 2 dose of CVX-045</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the potential for immunogenicity of CVX-045</measure>
    <time_frame>Days 1, 15, 1st day of every subsequent cycle, EOS, 30 Day FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To document any preliminary evidence of antitumor activity</measure>
    <time_frame>Every 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Neoplasms</condition>
  <condition>Carcinoma</condition>
  <condition>Cancer</condition>
  <condition>Malignancy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVX-045</intervention_name>
    <description>Weekly, intravenous dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed advanced solid tumors unresponsive to currently available therapies, or for
             which there is no standard therapy.

          -  Adequate coagulation, liver and renal function.

          -  Candidate for DCE-MRI evaluation.

          -  ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.

        Exclusion Criteria:

          -  Evidence of bleeding problems.

          -  Uncontrolled hypertension.

          -  Certain gastrointestinal problems including fistula and abscess.

          -  Patients with primary brain cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santa Monica,</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1121003&amp;StudyName=A%20%20Safety%20And%20Pharmacokinetic%20Study%20With%20CVX-045%20In%20Patients%20With%20Advanced%20Solid%20Tumors</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2009</study_first_posted>
  <last_update_submitted>December 10, 2010</last_update_submitted>
  <last_update_submitted_qc>December 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>CVX-045</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

